nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—BLK—systemic scleroderma	0.397	1	CbGaD
Crizotinib—PTK2B—Leflunomide—systemic scleroderma	0.251	0.859	CbGbCtD
Crizotinib—ABCB1—Lisinopril—systemic scleroderma	0.00899	0.0308	CbGbCtD
Crizotinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00814	0.0279	CbGbCtD
Crizotinib—ABCB1—Captopril—systemic scleroderma	0.00673	0.023	CbGbCtD
Crizotinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0053	0.0181	CbGbCtD
Crizotinib—ABCB1—Prednisone—systemic scleroderma	0.00424	0.0145	CbGbCtD
Crizotinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00317	0.0109	CbGbCtD
Crizotinib—CYP3A4—Prednisone—systemic scleroderma	0.00254	0.00869	CbGbCtD
Crizotinib—EPHA2—pulmonary artery—systemic scleroderma	0.0024	0.0274	CbGeAlD
Crizotinib—ABCB1—Methotrexate—systemic scleroderma	0.00212	0.00728	CbGbCtD
Crizotinib—MET—blood vessel—systemic scleroderma	0.00133	0.0152	CbGeAlD
Crizotinib—ROS1—tendon—systemic scleroderma	0.00124	0.0142	CbGeAlD
Crizotinib—TIE1—endothelium—systemic scleroderma	0.0011	0.0126	CbGeAlD
Crizotinib—ROS1—lung—systemic scleroderma	0.00109	0.0125	CbGeAlD
Crizotinib—MUSK—tendon—systemic scleroderma	0.00106	0.0121	CbGeAlD
Crizotinib—TIE1—blood vessel—systemic scleroderma	0.00102	0.0116	CbGeAlD
Crizotinib—RIPK2—endothelium—systemic scleroderma	0.000906	0.0103	CbGeAlD
Crizotinib—NEK9—connective tissue—systemic scleroderma	0.0009	0.0103	CbGeAlD
Crizotinib—TEK—artery—systemic scleroderma	0.000867	0.00989	CbGeAlD
Crizotinib—PTK2—endothelium—systemic scleroderma	0.000841	0.0096	CbGeAlD
Crizotinib—RIPK2—blood vessel—systemic scleroderma	0.000836	0.00953	CbGeAlD
Crizotinib—SIK2—connective tissue—systemic scleroderma	0.000809	0.00923	CbGeAlD
Crizotinib—CASK—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00079	0.221	CbGdCrCtD
Crizotinib—PTK2—blood vessel—systemic scleroderma	0.000776	0.00885	CbGeAlD
Crizotinib—SRC—artery—systemic scleroderma	0.000771	0.00879	CbGeAlD
Crizotinib—EPHB4—endothelium—systemic scleroderma	0.000766	0.00873	CbGeAlD
Crizotinib—PRKD1—smooth muscle tissue—systemic scleroderma	0.00075	0.00856	CbGeAlD
Crizotinib—TEK—endothelium—systemic scleroderma	0.000733	0.00836	CbGeAlD
Crizotinib—MAPK7—connective tissue—systemic scleroderma	0.000728	0.00831	CbGeAlD
Crizotinib—EPHB4—blood vessel—systemic scleroderma	0.000706	0.00805	CbGeAlD
Crizotinib—JAK2—blood vessel—systemic scleroderma	0.000701	0.008	CbGeAlD
Crizotinib—EPHA2—blood vessel—systemic scleroderma	0.000693	0.0079	CbGeAlD
Crizotinib—MET—connective tissue—systemic scleroderma	0.000682	0.00778	CbGeAlD
Crizotinib—TESK1—Enalapril—Captopril—systemic scleroderma	0.00068	0.19	CbGdCrCtD
Crizotinib—TEK—blood vessel—systemic scleroderma	0.000676	0.00771	CbGeAlD
Crizotinib—CDK7—connective tissue—systemic scleroderma	0.000659	0.00752	CbGeAlD
Crizotinib—SRC—endothelium—systemic scleroderma	0.000651	0.00743	CbGeAlD
Crizotinib—NEK9—digestive system—systemic scleroderma	0.00065	0.00741	CbGeAlD
Crizotinib—MET—skin of body—systemic scleroderma	0.000616	0.00702	CbGeAlD
Crizotinib—JAK3—connective tissue—systemic scleroderma	0.000601	0.00686	CbGeAlD
Crizotinib—SRC—blood vessel—systemic scleroderma	0.0006	0.00685	CbGeAlD
Crizotinib—CDK7—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000599	0.168	CbGdCrCtD
Crizotinib—PRKD1—digestive system—systemic scleroderma	0.000592	0.00676	CbGeAlD
Crizotinib—STK4—connective tissue—systemic scleroderma	0.00059	0.00673	CbGeAlD
Crizotinib—TYRO3—connective tissue—systemic scleroderma	0.000558	0.00636	CbGeAlD
Crizotinib—ALK—connective tissue—systemic scleroderma	0.000558	0.00636	CbGeAlD
Crizotinib—LIMK1—tendon—systemic scleroderma	0.000556	0.00634	CbGeAlD
Crizotinib—LYN—connective tissue—systemic scleroderma	0.000555	0.00633	CbGeAlD
Crizotinib—NEK9—lung—systemic scleroderma	0.000543	0.00619	CbGeAlD
Crizotinib—AURKA—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.000541	0.151	CbGdCrCtD
Crizotinib—IGF1R—connective tissue—systemic scleroderma	0.000536	0.00611	CbGeAlD
Crizotinib—TESK1—connective tissue—systemic scleroderma	0.000504	0.00575	CbGeAlD
Crizotinib—TYRO3—skin of body—systemic scleroderma	0.000504	0.00575	CbGeAlD
Crizotinib—MAPK7—tendon—systemic scleroderma	0.000501	0.00571	CbGeAlD
Crizotinib—FES—tendon—systemic scleroderma	0.000496	0.00565	CbGeAlD
Crizotinib—PRKD1—lung—systemic scleroderma	0.000495	0.00564	CbGeAlD
Crizotinib—MET—digestive system—systemic scleroderma	0.000492	0.00562	CbGeAlD
Crizotinib—IGF1R—smooth muscle tissue—systemic scleroderma	0.00049	0.00559	CbGeAlD
Crizotinib—IGF1R—skin of body—systemic scleroderma	0.000484	0.00552	CbGeAlD
Crizotinib—TIE1—smooth muscle tissue—systemic scleroderma	0.000477	0.00544	CbGeAlD
Crizotinib—PRKD3—lung—systemic scleroderma	0.000476	0.00542	CbGeAlD
Crizotinib—ACVR1—connective tissue—systemic scleroderma	0.000474	0.00541	CbGeAlD
Crizotinib—FLT3—connective tissue—systemic scleroderma	0.000474	0.00541	CbGeAlD
Crizotinib—MET—tendon—systemic scleroderma	0.000469	0.00535	CbGeAlD
Crizotinib—DSTYK—lung—systemic scleroderma	0.000464	0.00529	CbGeAlD
Crizotinib—LTK—lung—systemic scleroderma	0.000454	0.00518	CbGeAlD
Crizotinib—CASK—lung—systemic scleroderma	0.000454	0.00518	CbGeAlD
Crizotinib—TAOK2—tendon—systemic scleroderma	0.00045	0.00513	CbGeAlD
Crizotinib—BMP2K—connective tissue—systemic scleroderma	0.000447	0.0051	CbGeAlD
Crizotinib—MAPK7—lung—systemic scleroderma	0.000439	0.00501	CbGeAlD
Crizotinib—TXK—lung—systemic scleroderma	0.000439	0.00501	CbGeAlD
Crizotinib—FES—lung—systemic scleroderma	0.000435	0.00496	CbGeAlD
Crizotinib—JAK3—digestive system—systemic scleroderma	0.000434	0.00495	CbGeAlD
Crizotinib—PTK2B—connective tissue—systemic scleroderma	0.000432	0.00493	CbGeAlD
Crizotinib—DCLK1—digestive system—systemic scleroderma	0.000432	0.00492	CbGeAlD
Crizotinib—RIPK2—connective tissue—systemic scleroderma	0.000428	0.00489	CbGeAlD
Crizotinib—STK4—digestive system—systemic scleroderma	0.000426	0.00486	CbGeAlD
Crizotinib—STK35—skin of body—systemic scleroderma	0.00042	0.00479	CbGeAlD
Crizotinib—MET—lung—systemic scleroderma	0.000411	0.00469	CbGeAlD
Crizotinib—DCLK1—tendon—systemic scleroderma	0.000411	0.00468	CbGeAlD
Crizotinib—MAP3K2—connective tissue—systemic scleroderma	0.000406	0.00463	CbGeAlD
Crizotinib—ALK—digestive system—systemic scleroderma	0.000403	0.0046	CbGeAlD
Crizotinib—EPHA5—digestive system—systemic scleroderma	0.000403	0.0046	CbGeAlD
Crizotinib—CDK7—lung—systemic scleroderma	0.000398	0.00454	CbGeAlD
Crizotinib—PTK2—connective tissue—systemic scleroderma	0.000398	0.00454	CbGeAlD
Crizotinib—PTK2B—smooth muscle tissue—systemic scleroderma	0.000395	0.00451	CbGeAlD
Crizotinib—TYK2—connective tissue—systemic scleroderma	0.000395	0.00451	CbGeAlD
Crizotinib—TAOK2—lung—systemic scleroderma	0.000395	0.0045	CbGeAlD
Crizotinib—IGF1R—digestive system—systemic scleroderma	0.000387	0.00442	CbGeAlD
Crizotinib—RIPK2—skin of body—systemic scleroderma	0.000387	0.00441	CbGeAlD
Crizotinib—FER—tendon—systemic scleroderma	0.000383	0.00437	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—systemic scleroderma	0.000383	0.00436	CbGeAlD
Crizotinib—ACVR1B—lung—systemic scleroderma	0.00038	0.00434	CbGeAlD
Crizotinib—EPHA3—lung—systemic scleroderma	0.00038	0.00434	CbGeAlD
Crizotinib—TNK1—tendon—systemic scleroderma	0.000379	0.00433	CbGeAlD
Crizotinib—AXL—connective tissue—systemic scleroderma	0.000379	0.00432	CbGeAlD
Crizotinib—MAP4K1—tendon—systemic scleroderma	0.000376	0.00428	CbGeAlD
Crizotinib—AURKA—digestive system—systemic scleroderma	0.000367	0.00419	CbGeAlD
Crizotinib—PTK2—smooth muscle tissue—systemic scleroderma	0.000364	0.00415	CbGeAlD
Crizotinib—MAP4K2—tendon—systemic scleroderma	0.000363	0.00414	CbGeAlD
Crizotinib—JAK3—lung—systemic scleroderma	0.000363	0.00414	CbGeAlD
Crizotinib—EPHB4—connective tissue—systemic scleroderma	0.000362	0.00413	CbGeAlD
Crizotinib—TYK2—smooth muscle tissue—systemic scleroderma	0.000361	0.00412	CbGeAlD
Crizotinib—DCLK1—lung—systemic scleroderma	0.00036	0.00411	CbGeAlD
Crizotinib—JAK2—connective tissue—systemic scleroderma	0.000359	0.0041	CbGeAlD
Crizotinib—PTK2—skin of body—systemic scleroderma	0.000359	0.0041	CbGeAlD
Crizotinib—STK3—tendon—systemic scleroderma	0.000358	0.00409	CbGeAlD
Crizotinib—PLK4—lung—systemic scleroderma	0.000358	0.00409	CbGeAlD
Crizotinib—TYK2—skin of body—systemic scleroderma	0.000357	0.00407	CbGeAlD
Crizotinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.000357	0.00407	CbGeAlD
Crizotinib—STK4—lung—systemic scleroderma	0.000356	0.00406	CbGeAlD
Crizotinib—RPS6KB1—smooth muscle tissue—systemic scleroderma	0.00035	0.00399	CbGeAlD
Crizotinib—AURKA—tendon—systemic scleroderma	0.000349	0.00398	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—systemic scleroderma	0.000346	0.00395	CbGeAlD
Crizotinib—TEK—connective tissue—systemic scleroderma	0.000346	0.00395	CbGeAlD
Crizotinib—TESK1—tendon—systemic scleroderma	0.000346	0.00395	CbGeAlD
Crizotinib—AXL—skin of body—systemic scleroderma	0.000342	0.0039	CbGeAlD
Crizotinib—MERTK—tendon—systemic scleroderma	0.000337	0.00384	CbGeAlD
Crizotinib—ALK—lung—systemic scleroderma	0.000336	0.00384	CbGeAlD
Crizotinib—FER—lung—systemic scleroderma	0.000336	0.00384	CbGeAlD
Crizotinib—TNK1—lung—systemic scleroderma	0.000333	0.0038	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—systemic scleroderma	0.000331	0.00378	CbGeAlD
Crizotinib—MAP4K1—lung—systemic scleroderma	0.00033	0.00376	CbGeAlD
Crizotinib—BMPR1B—lung—systemic scleroderma	0.00033	0.00376	CbGeAlD
Crizotinib—MAP3K19—lung—systemic scleroderma	0.00033	0.00376	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—systemic scleroderma	0.000329	0.00375	CbGeAlD
Crizotinib—MAP3K12—tendon—systemic scleroderma	0.000326	0.00372	CbGeAlD
Crizotinib—ACVR1—tendon—systemic scleroderma	0.000326	0.00372	CbGeAlD
Crizotinib—JAK2—skin of body—systemic scleroderma	0.000325	0.0037	CbGeAlD
Crizotinib—TNK2—lung—systemic scleroderma	0.000323	0.00369	CbGeAlD
Crizotinib—IGF1R—lung—systemic scleroderma	0.000323	0.00369	CbGeAlD
Crizotinib—YES1—connective tissue—systemic scleroderma	0.00032	0.00365	CbGeAlD
Crizotinib—STK35—tendon—systemic scleroderma	0.000319	0.00364	CbGeAlD
Crizotinib—MAP4K2—lung—systemic scleroderma	0.000319	0.00364	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—systemic scleroderma	0.000317	0.00362	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—systemic scleroderma	0.000317	0.00362	CbGeAlD
Crizotinib—TAOK3—connective tissue—systemic scleroderma	0.000316	0.0036	CbGeAlD
Crizotinib—STK3—lung—systemic scleroderma	0.000314	0.00359	CbGeAlD
Crizotinib—TIE1—lung—systemic scleroderma	0.000314	0.00359	CbGeAlD
Crizotinib—MAP3K3—skin of body—systemic scleroderma	0.000313	0.00357	CbGeAlD
Crizotinib—PTK2B—digestive system—systemic scleroderma	0.000312	0.00356	CbGeAlD
Crizotinib—ABL2—tendon—systemic scleroderma	0.000311	0.00355	CbGeAlD
Crizotinib—RIPK2—digestive system—systemic scleroderma	0.000309	0.00353	CbGeAlD
Crizotinib—SRC—connective tissue—systemic scleroderma	0.000308	0.00351	CbGeAlD
Crizotinib—BMP2K—tendon—systemic scleroderma	0.000307	0.00351	CbGeAlD
Crizotinib—AURKA—lung—systemic scleroderma	0.000306	0.0035	CbGeAlD
Crizotinib—AURKA—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000306	0.0855	CbGdCrCtD
Crizotinib—TESK1—lung—systemic scleroderma	0.000304	0.00347	CbGeAlD
Crizotinib—EPHB6—skin of body—systemic scleroderma	0.000299	0.00341	CbGeAlD
Crizotinib—PTK2B—tendon—systemic scleroderma	0.000297	0.00339	CbGeAlD
Crizotinib—MERTK—lung—systemic scleroderma	0.000296	0.00337	CbGeAlD
Crizotinib—RIPK2—tendon—systemic scleroderma	0.000294	0.00336	CbGeAlD
Crizotinib—YES1—smooth muscle tissue—systemic scleroderma	0.000293	0.00334	CbGeAlD
Crizotinib—LIMK2—lung—systemic scleroderma	0.000289	0.0033	CbGeAlD
Crizotinib—NUAK2—lung—systemic scleroderma	0.000288	0.00329	CbGeAlD
Crizotinib—TBK1—digestive system—systemic scleroderma	0.000287	0.00328	CbGeAlD
Crizotinib—PTK2—digestive system—systemic scleroderma	0.000287	0.00328	CbGeAlD
Crizotinib—MAP3K12—lung—systemic scleroderma	0.000286	0.00326	CbGeAlD
Crizotinib—FLT3—lung—systemic scleroderma	0.000286	0.00326	CbGeAlD
Crizotinib—ACVR1—lung—systemic scleroderma	0.000286	0.00326	CbGeAlD
Crizotinib—TYK2—digestive system—systemic scleroderma	0.000285	0.00326	CbGeAlD
Crizotinib—EPHA4—tendon—systemic scleroderma	0.000285	0.00325	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—systemic scleroderma	0.000282	0.00321	CbGeAlD
Crizotinib—STK35—lung—systemic scleroderma	0.00028	0.0032	CbGeAlD
Crizotinib—SRC—skin of body—systemic scleroderma	0.000278	0.00317	CbGeAlD
Crizotinib—RPS6KB1—digestive system—systemic scleroderma	0.000276	0.00315	CbGeAlD
Crizotinib—CSF1R—connective tissue—systemic scleroderma	0.000276	0.00315	CbGeAlD
Crizotinib—FGR—digestive system—systemic scleroderma	0.000275	0.00313	CbGeAlD
Crizotinib—PTK2—tendon—systemic scleroderma	0.000273	0.00312	CbGeAlD
Crizotinib—TBK1—tendon—systemic scleroderma	0.000273	0.00312	CbGeAlD
Crizotinib—ABL2—lung—systemic scleroderma	0.000273	0.00312	CbGeAlD
Crizotinib—TYK2—tendon—systemic scleroderma	0.000272	0.0031	CbGeAlD
Crizotinib—BMP2K—lung—systemic scleroderma	0.00027	0.00308	CbGeAlD
Crizotinib—IRAK1—tendon—systemic scleroderma	0.000268	0.00306	CbGeAlD
Crizotinib—RPS6KB1—tendon—systemic scleroderma	0.000263	0.003	CbGeAlD
Crizotinib—EPHB4—digestive system—systemic scleroderma	0.000261	0.00298	CbGeAlD
Crizotinib—FGR—tendon—systemic scleroderma	0.000261	0.00298	CbGeAlD
Crizotinib—PTK2B—lung—systemic scleroderma	0.000261	0.00297	CbGeAlD
Crizotinib—AXL—tendon—systemic scleroderma	0.00026	0.00297	CbGeAlD
Crizotinib—JAK2—digestive system—systemic scleroderma	0.00026	0.00296	CbGeAlD
Crizotinib—RIPK2—lung—systemic scleroderma	0.000258	0.00295	CbGeAlD
Crizotinib—EPHA2—digestive system—systemic scleroderma	0.000256	0.00293	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000253	0.00288	CbGeAlD
Crizotinib—SLK—tendon—systemic scleroderma	0.000251	0.00286	CbGeAlD
Crizotinib—EPHA4—lung—systemic scleroderma	0.00025	0.00285	CbGeAlD
Crizotinib—CSF1R—skin of body—systemic scleroderma	0.00025	0.00285	CbGeAlD
Crizotinib—EPHB4—tendon—systemic scleroderma	0.000249	0.00284	CbGeAlD
Crizotinib—JAK2—tendon—systemic scleroderma	0.000247	0.00282	CbGeAlD
Crizotinib—MAP3K2—lung—systemic scleroderma	0.000245	0.00279	CbGeAlD
Crizotinib—EPHA2—tendon—systemic scleroderma	0.000244	0.00278	CbGeAlD
Crizotinib—PTK2—lung—systemic scleroderma	0.00024	0.00274	CbGeAlD
Crizotinib—TBK1—lung—systemic scleroderma	0.00024	0.00274	CbGeAlD
Crizotinib—TYK2—lung—systemic scleroderma	0.000238	0.00272	CbGeAlD
Crizotinib—MAP4K5—tendon—systemic scleroderma	0.000238	0.00272	CbGeAlD
Crizotinib—MAP3K3—tendon—systemic scleroderma	0.000238	0.00272	CbGeAlD
Crizotinib—TEK—tendon—systemic scleroderma	0.000238	0.00272	CbGeAlD
Crizotinib—IRAK1—lung—systemic scleroderma	0.000235	0.00268	CbGeAlD
Crizotinib—YES1—digestive system—systemic scleroderma	0.000231	0.00264	CbGeAlD
Crizotinib—RPS6KB1—lung—systemic scleroderma	0.000231	0.00263	CbGeAlD
Crizotinib—FGR—lung—systemic scleroderma	0.000229	0.00262	CbGeAlD
Crizotinib—LCK—lung—systemic scleroderma	0.000229	0.00262	CbGeAlD
Crizotinib—STK10—digestive system—systemic scleroderma	0.000229	0.00261	CbGeAlD
Crizotinib—AXL—lung—systemic scleroderma	0.000228	0.00261	CbGeAlD
Crizotinib—TAOK3—digestive system—systemic scleroderma	0.000228	0.0026	CbGeAlD
Crizotinib—EPHB6—tendon—systemic scleroderma	0.000228	0.0026	CbGeAlD
Crizotinib—TESK1—Enalapril—Lisinopril—systemic scleroderma	0.000224	0.0628	CbGdCrCtD
Crizotinib—SRC—digestive system—systemic scleroderma	0.000222	0.00254	CbGeAlD
Crizotinib—SLK—lung—systemic scleroderma	0.00022	0.00251	CbGeAlD
Crizotinib—YES1—tendon—systemic scleroderma	0.00022	0.00251	CbGeAlD
Crizotinib—ABL1—connective tissue—systemic scleroderma	0.000218	0.00249	CbGeAlD
Crizotinib—EPHB4—lung—systemic scleroderma	0.000218	0.00249	CbGeAlD
Crizotinib—STK10—tendon—systemic scleroderma	0.000218	0.00249	CbGeAlD
Crizotinib—TAOK3—tendon—systemic scleroderma	0.000217	0.00248	CbGeAlD
Crizotinib—JAK2—lung—systemic scleroderma	0.000217	0.00247	CbGeAlD
Crizotinib—Paraesthesia—Mometasone—systemic scleroderma	0.000214	0.00254	CcSEcCtD
Crizotinib—EPHA2—lung—systemic scleroderma	0.000214	0.00244	CbGeAlD
Crizotinib—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.000214	0.00253	CcSEcCtD
Crizotinib—Dyspnoea—Mometasone—systemic scleroderma	0.000213	0.00252	CcSEcCtD
Crizotinib—Bradycardia—Lisinopril—systemic scleroderma	0.000213	0.00252	CcSEcCtD
Crizotinib—Malnutrition—Leflunomide—systemic scleroderma	0.000212	0.00251	CcSEcCtD
Crizotinib—Respiratory failure—Methotrexate—systemic scleroderma	0.00021	0.00249	CcSEcCtD
Crizotinib—Dyspepsia—Mometasone—systemic scleroderma	0.00021	0.00249	CcSEcCtD
Crizotinib—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000209	0.00248	CcSEcCtD
Crizotinib—MAP3K3—lung—systemic scleroderma	0.000209	0.00238	CbGeAlD
Crizotinib—MAP4K5—lung—systemic scleroderma	0.000209	0.00238	CbGeAlD
Crizotinib—TEK—lung—systemic scleroderma	0.000209	0.00238	CbGeAlD
Crizotinib—Decreased appetite—Mometasone—systemic scleroderma	0.000207	0.00246	CcSEcCtD
Crizotinib—Dysgeusia—Leflunomide—systemic scleroderma	0.000207	0.00245	CcSEcCtD
Crizotinib—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.000207	0.00245	CcSEcCtD
Crizotinib—Anaemia—Azathioprine—systemic scleroderma	0.000207	0.00245	CcSEcCtD
Crizotinib—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00245	CcSEcCtD
Crizotinib—Pulmonary embolism—Methotrexate—systemic scleroderma	0.000207	0.00245	CcSEcCtD
Crizotinib—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000206	0.00244	CcSEcCtD
Crizotinib—Shock—Captopril—systemic scleroderma	0.000206	0.00244	CcSEcCtD
Crizotinib—Oedema peripheral—Lisinopril—systemic scleroderma	0.000206	0.00244	CcSEcCtD
Crizotinib—Fatigue—Mometasone—systemic scleroderma	0.000206	0.00244	CcSEcCtD
Crizotinib—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.000205	0.00243	CcSEcCtD
Crizotinib—Urethral disorder—Lisinopril—systemic scleroderma	0.000205	0.00243	CcSEcCtD
Crizotinib—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000204	0.00241	CcSEcCtD
Crizotinib—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000204	0.00241	CcSEcCtD
Crizotinib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000202	0.00239	CcSEcCtD
Crizotinib—Leukopenia—Azathioprine—systemic scleroderma	0.000201	0.00238	CcSEcCtD
Crizotinib—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00237	CcSEcCtD
Crizotinib—ABL1—smooth muscle tissue—systemic scleroderma	0.0002	0.00228	CbGeAlD
Crizotinib—EPHB6—lung—systemic scleroderma	0.0002	0.00228	CbGeAlD
Crizotinib—CSF1R—digestive system—systemic scleroderma	0.0002	0.00228	CbGeAlD
Crizotinib—Vision blurred—Leflunomide—systemic scleroderma	0.0002	0.00236	CcSEcCtD
Crizotinib—Asthenia—Pentoxifylline—systemic scleroderma	0.000198	0.00235	CcSEcCtD
Crizotinib—ABL1—skin of body—systemic scleroderma	0.000197	0.00225	CbGeAlD
Crizotinib—Anaemia—Leflunomide—systemic scleroderma	0.000196	0.00232	CcSEcCtD
Crizotinib—YES1—lung—systemic scleroderma	0.000193	0.0022	CbGeAlD
Crizotinib—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000193	0.00228	CcSEcCtD
Crizotinib—STK10—lung—systemic scleroderma	0.000191	0.00218	CbGeAlD
Crizotinib—TAOK3—lung—systemic scleroderma	0.000191	0.00217	CbGeAlD
Crizotinib—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00019	0.00225	CcSEcCtD
Crizotinib—CSF1R—tendon—systemic scleroderma	0.00019	0.00217	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00019	0.00224	CcSEcCtD
Crizotinib—Leukopenia—Leflunomide—systemic scleroderma	0.00019	0.00224	CcSEcCtD
Crizotinib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000189	0.00224	CcSEcCtD
Crizotinib—Body temperature increased—Mometasone—systemic scleroderma	0.000189	0.00223	CcSEcCtD
Crizotinib—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000188	0.00223	CcSEcCtD
Crizotinib—Paraesthesia—Captopril—systemic scleroderma	0.000188	0.00223	CcSEcCtD
Crizotinib—Dyspnoea—Captopril—systemic scleroderma	0.000187	0.00221	CcSEcCtD
Crizotinib—Arrhythmia—Lisinopril—systemic scleroderma	0.000187	0.00221	CcSEcCtD
Crizotinib—Anaemia—Mycophenolic acid—systemic scleroderma	0.000187	0.00221	CcSEcCtD
Crizotinib—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000186	0.00221	CcSEcCtD
Crizotinib—SRC—lung—systemic scleroderma	0.000186	0.00212	CbGeAlD
Crizotinib—Dyspepsia—Captopril—systemic scleroderma	0.000185	0.00218	CcSEcCtD
Crizotinib—Dizziness—Pentoxifylline—systemic scleroderma	0.000183	0.00217	CcSEcCtD
Crizotinib—Decreased appetite—Captopril—systemic scleroderma	0.000182	0.00216	CcSEcCtD
Crizotinib—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00216	CcSEcCtD
Crizotinib—Malnutrition—Lisinopril—systemic scleroderma	0.000182	0.00215	CcSEcCtD
Crizotinib—Infection—Azathioprine—systemic scleroderma	0.000182	0.00215	CcSEcCtD
Crizotinib—Syncope—Mycophenolic acid—systemic scleroderma	0.000181	0.00214	CcSEcCtD
Crizotinib—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00214	CcSEcCtD
Crizotinib—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000181	0.00214	CcSEcCtD
Crizotinib—Fatigue—Captopril—systemic scleroderma	0.000181	0.00214	CcSEcCtD
Crizotinib—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00018	0.00214	CcSEcCtD
Crizotinib—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000179	0.00213	CcSEcCtD
Crizotinib—Constipation—Captopril—systemic scleroderma	0.000179	0.00212	CcSEcCtD
Crizotinib—Sepsis—Methotrexate—systemic scleroderma	0.000179	0.00212	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000179	0.00212	CcSEcCtD
Crizotinib—Dysgeusia—Lisinopril—systemic scleroderma	0.000178	0.00211	CcSEcCtD
Crizotinib—Skin disorder—Azathioprine—systemic scleroderma	0.000178	0.0021	CcSEcCtD
Crizotinib—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000178	0.0021	CcSEcCtD
Crizotinib—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000176	0.00209	CcSEcCtD
Crizotinib—Vomiting—Pentoxifylline—systemic scleroderma	0.000176	0.00208	CcSEcCtD
Crizotinib—Rash—Pentoxifylline—systemic scleroderma	0.000174	0.00207	CcSEcCtD
Crizotinib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000174	0.00206	CcSEcCtD
Crizotinib—Face oedema—Prednisone—systemic scleroderma	0.000173	0.00205	CcSEcCtD
Crizotinib—Infection—Leflunomide—systemic scleroderma	0.000172	0.00203	CcSEcCtD
Crizotinib—Vision blurred—Lisinopril—systemic scleroderma	0.000171	0.00203	CcSEcCtD
Crizotinib—Asthenia—Mometasone—systemic scleroderma	0.000171	0.00203	CcSEcCtD
Crizotinib—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000171	0.00203	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000171	0.00202	CcSEcCtD
Crizotinib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00201	CcSEcCtD
Crizotinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000169	0.00201	CcSEcCtD
Crizotinib—Anaemia—Lisinopril—systemic scleroderma	0.000168	0.00199	CcSEcCtD
Crizotinib—Skin disorder—Leflunomide—systemic scleroderma	0.000168	0.00199	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—systemic scleroderma	0.000167	0.00198	CcSEcCtD
Crizotinib—CSF1R—lung—systemic scleroderma	0.000167	0.0019	CbGeAlD
Crizotinib—Body temperature increased—Captopril—systemic scleroderma	0.000166	0.00196	CcSEcCtD
Crizotinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000165	0.00195	CcSEcCtD
Crizotinib—Oedema—Mycophenolic acid—systemic scleroderma	0.000165	0.00195	CcSEcCtD
Crizotinib—Nausea—Pentoxifylline—systemic scleroderma	0.000164	0.00195	CcSEcCtD
Crizotinib—Infection—Mycophenolic acid—systemic scleroderma	0.000164	0.00194	CcSEcCtD
Crizotinib—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000164	0.00194	CcSEcCtD
Crizotinib—Diarrhoea—Mometasone—systemic scleroderma	0.000163	0.00193	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—systemic scleroderma	0.000163	0.00193	CcSEcCtD
Crizotinib—Syncope—Lisinopril—systemic scleroderma	0.000163	0.00193	CcSEcCtD
Crizotinib—Leukopenia—Lisinopril—systemic scleroderma	0.000163	0.00193	CcSEcCtD
Crizotinib—Shock—Mycophenolic acid—systemic scleroderma	0.000162	0.00192	CcSEcCtD
Crizotinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000162	0.00191	CcSEcCtD
Crizotinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00016	0.0019	CcSEcCtD
Crizotinib—Loss of consciousness—Lisinopril—systemic scleroderma	0.00016	0.00189	CcSEcCtD
Crizotinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00189	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—systemic scleroderma	0.000158	0.00187	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000158	0.00187	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—systemic scleroderma	0.000158	0.00187	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000158	0.00187	CcSEcCtD
Crizotinib—ABL1—digestive system—systemic scleroderma	0.000158	0.0018	CbGeAlD
Crizotinib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00185	CcSEcCtD
Crizotinib—Paraesthesia—Leflunomide—systemic scleroderma	0.000155	0.00184	CcSEcCtD
Crizotinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000154	0.00182	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000154	0.00182	CcSEcCtD
Crizotinib—Dyspepsia—Leflunomide—systemic scleroderma	0.000152	0.0018	CcSEcCtD
Crizotinib—Vomiting—Mometasone—systemic scleroderma	0.000152	0.0018	CcSEcCtD
Crizotinib—Rash—Mometasone—systemic scleroderma	0.00015	0.00178	CcSEcCtD
Crizotinib—Asthenia—Captopril—systemic scleroderma	0.00015	0.00178	CcSEcCtD
Crizotinib—Dermatitis—Mometasone—systemic scleroderma	0.00015	0.00178	CcSEcCtD
Crizotinib—Decreased appetite—Leflunomide—systemic scleroderma	0.00015	0.00178	CcSEcCtD
Crizotinib—ABL1—tendon—systemic scleroderma	0.00015	0.00171	CbGeAlD
Crizotinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000149	0.00177	CcSEcCtD
Crizotinib—Fatigue—Leflunomide—systemic scleroderma	0.000149	0.00176	CcSEcCtD
Crizotinib—Oedema—Lisinopril—systemic scleroderma	0.000148	0.00176	CcSEcCtD
Crizotinib—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000148	0.00175	CcSEcCtD
Crizotinib—Constipation—Leflunomide—systemic scleroderma	0.000148	0.00175	CcSEcCtD
Crizotinib—Infection—Lisinopril—systemic scleroderma	0.000147	0.00175	CcSEcCtD
Crizotinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000147	0.00174	CcSEcCtD
Crizotinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000147	0.00174	CcSEcCtD
Crizotinib—Shock—Lisinopril—systemic scleroderma	0.000146	0.00173	CcSEcCtD
Crizotinib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000145	0.00172	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—systemic scleroderma	0.000145	0.00172	CcSEcCtD
Crizotinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000145	0.00171	CcSEcCtD
Crizotinib—Skin disorder—Lisinopril—systemic scleroderma	0.000144	0.00171	CcSEcCtD
Crizotinib—Diarrhoea—Captopril—systemic scleroderma	0.000143	0.0017	CcSEcCtD
Crizotinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000143	0.0017	CcSEcCtD
Crizotinib—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00169	CcSEcCtD
Crizotinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00169	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000142	0.00168	CcSEcCtD
Crizotinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000142	0.00168	CcSEcCtD
Crizotinib—Nausea—Mometasone—systemic scleroderma	0.000142	0.00168	CcSEcCtD
Crizotinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000141	0.00167	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—systemic scleroderma	0.00014	0.00166	CcSEcCtD
Crizotinib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00014	0.00166	CcSEcCtD
Crizotinib—Dizziness—Captopril—systemic scleroderma	0.000139	0.00164	CcSEcCtD
Crizotinib—Body temperature increased—Leflunomide—systemic scleroderma	0.000137	0.00162	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000136	0.0016	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000135	0.0016	CcSEcCtD
Crizotinib—Paraesthesia—Lisinopril—systemic scleroderma	0.000133	0.00158	CcSEcCtD
Crizotinib—Vomiting—Captopril—systemic scleroderma	0.000133	0.00158	CcSEcCtD
Crizotinib—ABCB1—blood vessel—systemic scleroderma	0.000132	0.00151	CbGeAlD
Crizotinib—Dyspnoea—Lisinopril—systemic scleroderma	0.000132	0.00157	CcSEcCtD
Crizotinib—Rash—Captopril—systemic scleroderma	0.000132	0.00157	CcSEcCtD
Crizotinib—Dermatitis—Captopril—systemic scleroderma	0.000132	0.00156	CcSEcCtD
Crizotinib—ABL1—lung—systemic scleroderma	0.000132	0.0015	CbGeAlD
Crizotinib—Dyspepsia—Lisinopril—systemic scleroderma	0.000131	0.00155	CcSEcCtD
Crizotinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00013	0.00154	CcSEcCtD
Crizotinib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00154	CcSEcCtD
Crizotinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000129	0.00153	CcSEcCtD
Crizotinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000129	0.00153	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000128	0.00152	CcSEcCtD
Crizotinib—Fatigue—Lisinopril—systemic scleroderma	0.000128	0.00152	CcSEcCtD
Crizotinib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000128	0.00152	CcSEcCtD
Crizotinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000128	0.00151	CcSEcCtD
Crizotinib—Constipation—Lisinopril—systemic scleroderma	0.000127	0.0015	CcSEcCtD
Crizotinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000126	0.0015	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—systemic scleroderma	0.000126	0.0015	CcSEcCtD
Crizotinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000125	0.00148	CcSEcCtD
Crizotinib—Nausea—Captopril—systemic scleroderma	0.000125	0.00147	CcSEcCtD
Crizotinib—Asthenia—Leflunomide—systemic scleroderma	0.000124	0.00147	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—systemic scleroderma	0.000121	0.00143	CcSEcCtD
Crizotinib—Dizziness—Azathioprine—systemic scleroderma	0.000121	0.00143	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00012	0.00143	CcSEcCtD
Crizotinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000118	0.0014	CcSEcCtD
Crizotinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000118	0.0014	CcSEcCtD
Crizotinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000117	0.00139	CcSEcCtD
Crizotinib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000117	0.00138	CcSEcCtD
Crizotinib—Vomiting—Azathioprine—systemic scleroderma	0.000116	0.00138	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—systemic scleroderma	0.000116	0.00138	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—systemic scleroderma	0.000116	0.00137	CcSEcCtD
Crizotinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00137	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000116	0.00137	CcSEcCtD
Crizotinib—Infestation—Methotrexate—systemic scleroderma	0.000116	0.00137	CcSEcCtD
Crizotinib—Rash—Azathioprine—systemic scleroderma	0.000115	0.00137	CcSEcCtD
Crizotinib—Dermatitis—Azathioprine—systemic scleroderma	0.000115	0.00136	CcSEcCtD
Crizotinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00136	CcSEcCtD
Crizotinib—Dizziness—Leflunomide—systemic scleroderma	0.000114	0.00135	CcSEcCtD
Crizotinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000113	0.00134	CcSEcCtD
Crizotinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000113	0.00134	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00133	CcSEcCtD
Crizotinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000111	0.00132	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—systemic scleroderma	0.000111	0.00131	CcSEcCtD
Crizotinib—Vomiting—Leflunomide—systemic scleroderma	0.00011	0.0013	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000109	0.00129	CcSEcCtD
Crizotinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000109	0.00129	CcSEcCtD
Crizotinib—Rash—Leflunomide—systemic scleroderma	0.000109	0.00129	CcSEcCtD
Crizotinib—Dermatitis—Leflunomide—systemic scleroderma	0.000109	0.00129	CcSEcCtD
Crizotinib—Nausea—Azathioprine—systemic scleroderma	0.000109	0.00129	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—systemic scleroderma	0.000108	0.00128	CcSEcCtD
Crizotinib—Asthenia—Lisinopril—systemic scleroderma	0.000107	0.00126	CcSEcCtD
Crizotinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000105	0.00124	CcSEcCtD
Crizotinib—Rash—Mycophenolic acid—systemic scleroderma	0.000104	0.00123	CcSEcCtD
Crizotinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000104	0.00123	CcSEcCtD
Crizotinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000103	0.00122	CcSEcCtD
Crizotinib—Nausea—Leflunomide—systemic scleroderma	0.000103	0.00122	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000102	0.00121	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—systemic scleroderma	0.000102	0.00121	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—systemic scleroderma	0.000102	0.0012	CcSEcCtD
Crizotinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000102	0.0012	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—systemic scleroderma	0.0001	0.00118	CcSEcCtD
Crizotinib—Anaemia—Prednisone—systemic scleroderma	9.99e-05	0.00118	CcSEcCtD
Crizotinib—Dizziness—Lisinopril—systemic scleroderma	9.82e-05	0.00116	CcSEcCtD
Crizotinib—Nausea—Mycophenolic acid—systemic scleroderma	9.79e-05	0.00116	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—systemic scleroderma	9.69e-05	0.00115	CcSEcCtD
Crizotinib—Syncope—Prednisone—systemic scleroderma	9.69e-05	0.00115	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—systemic scleroderma	9.63e-05	0.00114	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—systemic scleroderma	9.5e-05	0.00112	CcSEcCtD
Crizotinib—Vomiting—Lisinopril—systemic scleroderma	9.44e-05	0.00112	CcSEcCtD
Crizotinib—Rash—Lisinopril—systemic scleroderma	9.36e-05	0.00111	CcSEcCtD
Crizotinib—Dermatitis—Lisinopril—systemic scleroderma	9.35e-05	0.00111	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—systemic scleroderma	9.35e-05	0.00111	CcSEcCtD
Crizotinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.00111	CcSEcCtD
Crizotinib—CYP3A5—digestive system—systemic scleroderma	9.23e-05	0.00105	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	9.13e-05	0.00108	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—systemic scleroderma	9.03e-05	0.00107	CcSEcCtD
Crizotinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.9e-05	0.00105	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—systemic scleroderma	8.84e-05	0.00105	CcSEcCtD
Crizotinib—Nausea—Lisinopril—systemic scleroderma	8.82e-05	0.00104	CcSEcCtD
Crizotinib—Oedema—Prednisone—systemic scleroderma	8.82e-05	0.00104	CcSEcCtD
Crizotinib—Infection—Prednisone—systemic scleroderma	8.76e-05	0.00104	CcSEcCtD
Crizotinib—Shock—Prednisone—systemic scleroderma	8.68e-05	0.00103	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—systemic scleroderma	8.65e-05	0.00102	CcSEcCtD
Crizotinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.6e-05	0.00102	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—systemic scleroderma	8.56e-05	0.00101	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Mometasone—systemic scleroderma	8.54e-05	0.0239	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Mometasone—systemic scleroderma	8.54e-05	0.0239	CbGdCrCtD
Crizotinib—Vision blurred—Methotrexate—systemic scleroderma	8.51e-05	0.00101	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—systemic scleroderma	8.35e-05	0.000988	CcSEcCtD
Crizotinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000979	CcSEcCtD
Crizotinib—Rash—Mycophenolate mofetil—systemic scleroderma	8.2e-05	0.000971	CcSEcCtD
Crizotinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.19e-05	0.00097	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—systemic scleroderma	8.08e-05	0.000957	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—systemic scleroderma	7.92e-05	0.000937	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—systemic scleroderma	7.76e-05	0.000919	CcSEcCtD
Crizotinib—Nausea—Mycophenolate mofetil—systemic scleroderma	7.73e-05	0.000915	CcSEcCtD
Crizotinib—CYP3A5—lung—systemic scleroderma	7.71e-05	0.00088	CbGeAlD
Crizotinib—Decreased appetite—Prednisone—systemic scleroderma	7.67e-05	0.000908	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.63e-05	0.000904	CcSEcCtD
Crizotinib—Fatigue—Prednisone—systemic scleroderma	7.6e-05	0.0009	CcSEcCtD
Crizotinib—Constipation—Prednisone—systemic scleroderma	7.54e-05	0.000893	CcSEcCtD
Crizotinib—Infection—Methotrexate—systemic scleroderma	7.32e-05	0.000867	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—systemic scleroderma	7.23e-05	0.000856	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—systemic scleroderma	7.16e-05	0.000847	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—systemic scleroderma	6.97e-05	0.000825	CcSEcCtD
Crizotinib—CYP3A4—digestive system—systemic scleroderma	6.93e-05	0.000791	CbGeAlD
Crizotinib—Paraesthesia—Methotrexate—systemic scleroderma	6.62e-05	0.000783	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—systemic scleroderma	6.57e-05	0.000778	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—systemic scleroderma	6.49e-05	0.000768	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—systemic scleroderma	6.41e-05	0.000758	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.36e-05	0.000753	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—systemic scleroderma	6.35e-05	0.000752	CcSEcCtD
Crizotinib—Asthenia—Prednisone—systemic scleroderma	6.33e-05	0.000749	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—systemic scleroderma	6.03e-05	0.000714	CcSEcCtD
Crizotinib—Dizziness—Prednisone—systemic scleroderma	5.83e-05	0.00069	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—systemic scleroderma	5.83e-05	0.00069	CcSEcCtD
Crizotinib—Vomiting—Prednisone—systemic scleroderma	5.61e-05	0.000664	CcSEcCtD
Crizotinib—Rash—Prednisone—systemic scleroderma	5.56e-05	0.000658	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—systemic scleroderma	5.55e-05	0.000658	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Mometasone—systemic scleroderma	5.51e-05	0.0154	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Mometasone—systemic scleroderma	5.51e-05	0.0154	CbGdCrCtD
Crizotinib—Asthenia—Methotrexate—systemic scleroderma	5.29e-05	0.000626	CcSEcCtD
Crizotinib—Nausea—Prednisone—systemic scleroderma	5.24e-05	0.00062	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—systemic scleroderma	5.04e-05	0.000597	CcSEcCtD
Crizotinib—ABCB1—digestive system—systemic scleroderma	4.91e-05	0.00056	CbGeAlD
Crizotinib—Dizziness—Methotrexate—systemic scleroderma	4.87e-05	0.000577	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—systemic scleroderma	4.69e-05	0.000555	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—systemic scleroderma	4.66e-05	0.013	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—systemic scleroderma	4.66e-05	0.013	CbGdCrCtD
Crizotinib—Rash—Methotrexate—systemic scleroderma	4.65e-05	0.00055	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—systemic scleroderma	4.64e-05	0.00055	CcSEcCtD
Crizotinib—Nausea—Methotrexate—systemic scleroderma	4.38e-05	0.000518	CcSEcCtD
Crizotinib—ABCB1—lung—systemic scleroderma	4.1e-05	0.000467	CbGeAlD
Crizotinib—TESK1—Dexamethasone—Prednisone—systemic scleroderma	3e-05	0.0084	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—systemic scleroderma	3e-05	0.0084	CbGdCrCtD
Crizotinib—AXL—Signaling Pathways—NOS3—systemic scleroderma	7.85e-06	5.82e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CSK—systemic scleroderma	7.83e-06	5.8e-05	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	7.8e-06	5.78e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—CCL2—systemic scleroderma	7.79e-06	5.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BLK—systemic scleroderma	7.78e-06	5.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD247—systemic scleroderma	7.76e-06	5.75e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRF5—systemic scleroderma	7.7e-06	5.71e-05	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—TGFB1—systemic scleroderma	7.68e-06	5.69e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CSK—systemic scleroderma	7.63e-06	5.65e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-DQB1—systemic scleroderma	7.62e-06	5.65e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	7.57e-06	5.62e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-DQB1—systemic scleroderma	7.52e-06	5.57e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HSPG2—systemic scleroderma	7.48e-06	5.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	7.47e-06	5.54e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRF8—systemic scleroderma	7.36e-06	5.46e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ITGAM—systemic scleroderma	7.36e-06	5.46e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD247—systemic scleroderma	7.36e-06	5.46e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IL1B—systemic scleroderma	7.31e-06	5.42e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IL1B—systemic scleroderma	7.31e-06	5.42e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1A—systemic scleroderma	7.24e-06	5.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EDN1—systemic scleroderma	7.24e-06	5.37e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CSK—systemic scleroderma	7.23e-06	5.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD40LG—systemic scleroderma	7.2e-06	5.34e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	7.18e-06	5.33e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—NOS3—systemic scleroderma	7.18e-06	5.32e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	7.15e-06	5.3e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1A—systemic scleroderma	7.14e-06	5.29e-05	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—MMP9—systemic scleroderma	7.13e-06	5.29e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-DQB1—systemic scleroderma	7.13e-06	5.29e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD40LG—systemic scleroderma	7.1e-06	5.26e-05	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—MMP9—systemic scleroderma	7.1e-06	5.26e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—CCL2—systemic scleroderma	7.04e-06	5.22e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—MMP1—systemic scleroderma	7.03e-06	5.22e-05	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	6.97e-06	5.17e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CSK—systemic scleroderma	6.93e-06	5.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-DQB1—systemic scleroderma	6.92e-06	5.13e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—MMP9—systemic scleroderma	6.92e-06	5.13e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—TNFAIP3—systemic scleroderma	6.89e-06	5.11e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP2—systemic scleroderma	6.88e-06	5.1e-05	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—TGFB1—systemic scleroderma	6.84e-06	5.07e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—MMP9—systemic scleroderma	6.82e-06	5.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRF5—systemic scleroderma	6.82e-06	5.06e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—BLK—systemic scleroderma	6.81e-06	5.05e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTLA4—systemic scleroderma	6.81e-06	5.05e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD247—systemic scleroderma	6.8e-06	5.04e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RHOB—systemic scleroderma	6.78e-06	5.03e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTLA4—systemic scleroderma	6.77e-06	5.02e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1A—systemic scleroderma	6.77e-06	5.02e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP2—systemic scleroderma	6.77e-06	5.02e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	6.74e-06	5e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD40LG—systemic scleroderma	6.73e-06	4.99e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EDN1—systemic scleroderma	6.73e-06	4.99e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-DQB1—systemic scleroderma	6.7e-06	4.97e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MMP9—systemic scleroderma	6.67e-06	4.95e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—MMP9—systemic scleroderma	6.64e-06	4.92e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—MMP9—systemic scleroderma	6.64e-06	4.92e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HSPG2—systemic scleroderma	6.63e-06	4.91e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1A—systemic scleroderma	6.57e-06	4.87e-05	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	6.54e-06	4.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD40LG—systemic scleroderma	6.54e-06	4.85e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TGFB1—systemic scleroderma	6.53e-06	4.84e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRF8—systemic scleroderma	6.52e-06	4.83e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ITGAM—systemic scleroderma	6.52e-06	4.83e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD247—systemic scleroderma	6.52e-06	4.83e-05	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.51e-06	4.83e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CSK—systemic scleroderma	6.4e-06	4.74e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	6.39e-06	4.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTLA4—systemic scleroderma	6.37e-06	4.72e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CCL2—systemic scleroderma	6.36e-06	4.72e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SMAD7—systemic scleroderma	6.36e-06	4.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RHOB—systemic scleroderma	6.35e-06	4.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP2—systemic scleroderma	6.34e-06	4.7e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD40LG—systemic scleroderma	6.33e-06	4.69e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—MMP9—systemic scleroderma	6.29e-06	4.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MMP9—systemic scleroderma	6.28e-06	4.66e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—NOS3—systemic scleroderma	6.27e-06	4.65e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CCL2—systemic scleroderma	6.23e-06	4.62e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—MMP1—systemic scleroderma	6.23e-06	4.62e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—NOS3—systemic scleroderma	6.22e-06	4.61e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—NOS3—systemic scleroderma	6.19e-06	4.59e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CSK—systemic scleroderma	6.18e-06	4.58e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TNFAIP3—systemic scleroderma	6.1e-06	4.52e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—EDN1—systemic scleroderma	6.04e-06	4.48e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—BLK—systemic scleroderma	6.03e-06	4.47e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD247—systemic scleroderma	6.02e-06	4.46e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EDN1—systemic scleroderma	6e-06	4.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HSPG2—systemic scleroderma	5.98e-06	4.44e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL1B—systemic scleroderma	5.97e-06	4.42e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EDN1—systemic scleroderma	5.91e-06	4.38e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—NOS3—systemic scleroderma	5.82e-06	4.32e-05	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	5.79e-06	4.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CSK—systemic scleroderma	5.78e-06	4.28e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MMP9—systemic scleroderma	5.76e-06	4.27e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL1B—systemic scleroderma	5.72e-06	4.24e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TGFB1—systemic scleroderma	5.7e-06	4.23e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—NOS3—systemic scleroderma	5.67e-06	4.21e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EDN1—systemic scleroderma	5.66e-06	4.2e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TGFB1—systemic scleroderma	5.62e-06	4.17e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-DQB1—systemic scleroderma	5.6e-06	4.16e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TGFB1—systemic scleroderma	5.59e-06	4.15e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTLA4—systemic scleroderma	5.58e-06	4.14e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	5.58e-06	4.14e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	5.56e-06	4.12e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—NOS3—systemic scleroderma	5.55e-06	4.12e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TGFB1—systemic scleroderma	5.52e-06	4.09e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EDN1—systemic scleroderma	5.49e-06	4.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EDN1—systemic scleroderma	5.48e-06	4.07e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TGFB1—systemic scleroderma	5.47e-06	4.06e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TGFB1—systemic scleroderma	5.47e-06	4.06e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—NOS3—systemic scleroderma	5.47e-06	4.06e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL1B—systemic scleroderma	5.4e-06	4e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1A—systemic scleroderma	5.32e-06	3.95e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1A—systemic scleroderma	5.3e-06	3.93e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40LG—systemic scleroderma	5.29e-06	3.92e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40LG—systemic scleroderma	5.27e-06	3.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-DQB1—systemic scleroderma	5.24e-06	3.89e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	5.24e-06	3.89e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TGFB1—systemic scleroderma	5.19e-06	3.85e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TGFB1—systemic scleroderma	5.18e-06	3.84e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP9—systemic scleroderma	5.17e-06	3.84e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NOS3—systemic scleroderma	5.1e-06	3.78e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP9—systemic scleroderma	5.09e-06	3.77e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	5.06e-06	3.76e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CSK—systemic scleroderma	5.06e-06	3.75e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MMP9—systemic scleroderma	5.03e-06	3.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1A—systemic scleroderma	4.98e-06	3.69e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40LG—systemic scleroderma	4.95e-06	3.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—CCL2—systemic scleroderma	4.95e-06	3.67e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTLA4—systemic scleroderma	4.94e-06	3.66e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RHOB—systemic scleroderma	4.92e-06	3.65e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP2—systemic scleroderma	4.91e-06	3.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL1B—systemic scleroderma	4.81e-06	3.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP9—systemic scleroderma	4.76e-06	3.53e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TGFB1—systemic scleroderma	4.75e-06	3.52e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL1B—systemic scleroderma	4.74e-06	3.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EDN1—systemic scleroderma	4.71e-06	3.49e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EDN1—systemic scleroderma	4.64e-06	3.44e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HSPG2—systemic scleroderma	4.64e-06	3.44e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL1B—systemic scleroderma	4.63e-06	3.43e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL1B—systemic scleroderma	4.61e-06	3.42e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CCL2—systemic scleroderma	4.6e-06	3.41e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	4.59e-06	3.41e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MMP9—systemic scleroderma	4.55e-06	3.37e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NOS3—systemic scleroderma	4.51e-06	3.35e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CSK—systemic scleroderma	4.48e-06	3.32e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MMP9—systemic scleroderma	4.45e-06	3.3e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	4.4e-06	3.26e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1A—systemic scleroderma	4.36e-06	3.23e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	4.35e-06	3.23e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40LG—systemic scleroderma	4.34e-06	3.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EDN1—systemic scleroderma	4.27e-06	3.17e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TGFB1—systemic scleroderma	4.19e-06	3.11e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	4.17e-06	3.09e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TGFB1—systemic scleroderma	4.15e-06	3.08e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TGFB1—systemic scleroderma	4.11e-06	3.05e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCL2—systemic scleroderma	4.1e-06	3.04e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NOS3—systemic scleroderma	4.1e-06	3.04e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	4.09e-06	3.04e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DQB1—systemic scleroderma	4.07e-06	3.02e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCL2—systemic scleroderma	4.04e-06	3e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TGFB1—systemic scleroderma	3.92e-06	2.91e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCL2—systemic scleroderma	3.87e-06	2.87e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1A—systemic scleroderma	3.86e-06	2.86e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.85e-06	2.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TGFB1—systemic scleroderma	3.85e-06	2.85e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40LG—systemic scleroderma	3.84e-06	2.85e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—systemic scleroderma	3.78e-06	2.8e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCL2—systemic scleroderma	3.75e-06	2.78e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TGFB1—systemic scleroderma	3.75e-06	2.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CCL2—systemic scleroderma	3.75e-06	2.78e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—systemic scleroderma	3.72e-06	2.76e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS3—systemic scleroderma	3.72e-06	2.76e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP9—systemic scleroderma	3.69e-06	2.74e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TGFB1—systemic scleroderma	3.67e-06	2.72e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NOS3—systemic scleroderma	3.66e-06	2.71e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—TGFB1—systemic scleroderma	3.62e-06	2.68e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NOS3—systemic scleroderma	3.6e-06	2.67e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—systemic scleroderma	3.53e-06	2.62e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EDN1—systemic scleroderma	3.46e-06	2.57e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NOS3—systemic scleroderma	3.45e-06	2.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—systemic scleroderma	3.43e-06	2.54e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TGFB1—systemic scleroderma	3.37e-06	2.5e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NOS3—systemic scleroderma	3.34e-06	2.48e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	3.3e-06	2.44e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—systemic scleroderma	3.29e-06	2.44e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.28e-06	2.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDN1—systemic scleroderma	3.24e-06	2.4e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCL2—systemic scleroderma	3.22e-06	2.39e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCL2—systemic scleroderma	3.17e-06	2.35e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TGFB1—systemic scleroderma	3.04e-06	2.26e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	3.01e-06	2.23e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—systemic scleroderma	2.99e-06	2.21e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—systemic scleroderma	2.93e-06	2.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL2—systemic scleroderma	2.92e-06	2.17e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—systemic scleroderma	2.89e-06	2.14e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—systemic scleroderma	2.87e-06	2.13e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	2.84e-06	2.1e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—systemic scleroderma	2.83e-06	2.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—systemic scleroderma	2.82e-06	2.09e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—systemic scleroderma	2.78e-06	2.06e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—systemic scleroderma	2.77e-06	2.05e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—systemic scleroderma	2.76e-06	2.05e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—systemic scleroderma	2.71e-06	2.01e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	2.68e-06	1.99e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—systemic scleroderma	2.68e-06	1.99e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—systemic scleroderma	2.6e-06	1.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—systemic scleroderma	2.6e-06	1.93e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDN1—systemic scleroderma	2.51e-06	1.86e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CTGF—systemic scleroderma	2.49e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—systemic scleroderma	2.47e-06	1.83e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—systemic scleroderma	2.46e-06	1.82e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—systemic scleroderma	2.42e-06	1.79e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—systemic scleroderma	2.38e-06	1.77e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—systemic scleroderma	2.37e-06	1.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—systemic scleroderma	2.3e-06	1.71e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—systemic scleroderma	2.28e-06	1.69e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—systemic scleroderma	2.28e-06	1.69e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—systemic scleroderma	2.27e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—systemic scleroderma	2.21e-06	1.64e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—systemic scleroderma	2.21e-06	1.64e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—systemic scleroderma	2.19e-06	1.62e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	2.15e-06	1.6e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—systemic scleroderma	2.11e-06	1.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—systemic scleroderma	2.09e-06	1.55e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.02e-06	1.5e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—systemic scleroderma	2.01e-06	1.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—systemic scleroderma	1.97e-06	1.46e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	1.94e-06	1.44e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—systemic scleroderma	1.9e-06	1.41e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—systemic scleroderma	1.87e-06	1.39e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—systemic scleroderma	1.86e-06	1.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.77e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	1.73e-06	1.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—systemic scleroderma	1.72e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—systemic scleroderma	1.72e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—systemic scleroderma	1.69e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—systemic scleroderma	1.63e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—systemic scleroderma	1.58e-06	1.17e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.53e-06	1.14e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—systemic scleroderma	1.53e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—systemic scleroderma	1.45e-06	1.07e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.44e-06	1.06e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	1.39e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	1.39e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—systemic scleroderma	1.31e-06	9.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—systemic scleroderma	1.23e-06	9.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	1.14e-06	8.48e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—systemic scleroderma	1.08e-06	8.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—systemic scleroderma	1.01e-06	7.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.67e-07	4.95e-06	CbGpPWpGaD
